コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 Nav1.5 blocking properties of fluoxetine, a selective serotonin reuptake inhibitor.
2 lerance or lack of remission with an initial selective serotonin reuptake inhibitor.
3 lesions; both behaviours are alleviated by a selective serotonin reuptake inhibitor.
4 owing would be unresponsive to fluoxetine, a selective serotonin reuptake inhibitor.
5 serotonin in rat frontal cortex typical of a selective serotonin reuptake inhibitor.
6 al hippocampus following administration of a selective serotonin reuptake inhibitor.
7 CK1) inhibitor, the other from paroxetine, a selective serotonin-reuptake inhibitor.
8 hotics to Depressive patients medicated with Selective Serotonin Reuptake Inhibitors.
9 hypersensitivity, and response to long-term selective serotonin reuptake inhibitors.
10 ve add-on in patients that do not respond to selective serotonin reuptake inhibitors.
11 tment in the absence of prenatal exposure to selective serotonin reuptake inhibitors.
12 more sensitive to SERT inhibitors, including selective serotonin reuptake inhibitors.
13 ic dementia, often respond to treatment with selective serotonin reuptake inhibitors.
14 ries the same FDA "black box" warning as the selective serotonin reuptake inhibitors.
15 ples; and pharmacological treatments, mainly selective serotonin reuptake inhibitors.
16 ffects beyond 12 weeks outside of those with selective serotonin reuptake inhibitors.
17 .90), compared with patients who did not use selective serotonin reuptake inhibitors.
18 (S allele) results in decreased efficacy of selective serotonin reuptake inhibitors.
19 s and appears to lack drug interactions with selective serotonin reuptake inhibitors.
20 d in mediating the antidepressant actions of selective serotonin reuptake inhibitors.
22 I was significantly lower in patients taking selective serotonin reuptake inhibitors (adjusted hazard
25 summarizes recent developments in the use of selective serotonin reuptake inhibitors and atypical ant
27 onin transporter (5-HTT) is a key target for selective serotonin reuptake inhibitors and may be invol
28 onflicting evidence and guidelines regarding selective serotonin reuptake inhibitors and suicidality
30 5), benzodiazepines (-0.96, -1.56 to -0.36), selective serotonin-reuptake inhibitors and serotonin-no
31 and pharmacological treatments, particularly selective serotonin-reuptake inhibitors and serotonin-no
32 nin in healthy volunteers with citalopram (a selective serotonin reuptake inhibitor) and contrasted i
33 s fluids, benzodiazapines, and withdrawal of selective serotonin-reuptake inhibitor) and received cyp
34 e transgenerational effects of sertraline, a selective serotonin reuptake inhibitor, and venlafaxine,
35 ective, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and a new agent
36 drugs, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and norepinephr
37 ents, such as atypical antipsychotic agents, selective serotonin reuptake inhibitors, and selective s
38 treatment-related issues: suicide risk with selective serotonin reuptake inhibitors, and the safety
39 We use this line to demonstrate that the selective serotonin reuptake inhibitor antidepressant fl
40 deficits and that the neurogenic effects of selective serotonin reuptake inhibitor antidepressants c
42 , but not acute, treatment with tricyclic or selective serotonin reuptake inhibitor antidepressants.
43 of fluoxetine, and thus it remains the only selective serotonin reuptake inhibitor approved by the U
48 ent evidence continues to support the use of selective serotonin reuptake inhibitors as first-line ph
49 anwhile, evidence supporting the efficacy of selective serotonin reuptake inhibitors, augmentation st
50 a slight shift in prescribing toward the non-selective serotonin reuptake inhibitor bupropion hydroch
51 d risk of ASD associated with treatment with selective serotonin reuptake inhibitors by the mother du
52 ed the 10-year risk of MOF by 36% for use of selective serotonin reuptake inhibitors, by 63% for use
53 -year risk of hip fracture by 57% for use of selective serotonin reuptake inhibitors, by 98% for use
54 ized in a double-blind design to receive the selective serotonin reuptake inhibitor citalopram (20 mg
59 ogical antagonists (BI-11A7 and BI-2A7); the selective serotonin reuptake inhibitor citalopram was us
61 ological challenge with an acute dose of the selective serotonin reuptake inhibitor, citalopram, reve
64 xamined whether fluoxetine, the prototypical selective serotonin reuptake inhibitor, differentially m
65 her genetic deletion or brief treatment with selective serotonin reuptake inhibitors during developme
67 m effects of exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, during adolescen
69 rimary target for antidepressants, including selective serotonin reuptake inhibitors (e.g. (S)-citalo
71 ed during 8 weeks with either placebo or the selective serotonin reuptake inhibitor escitalopram.
72 ssociated with subsequent remission with the selective serotonin reuptake inhibitor escitalopram; thi
73 allele responded significantly better to the selective serotonin reuptake inhibitors escitalopram and
74 tment and 8 weeks after randomization to the selective serotonin reuptake inhibitors escitalopram and
75 tigated whether a 3-week administration of a selective serotonin reuptake inhibitor, expected to incr
77 ramine, instead mirrored the behavior of the selective serotonin reuptake inhibitor fluoxetine, both
81 -HT transport and binding of cocaine and the selective serotonin reuptake inhibitors fluoxetine and e
82 inhibits the antidepressant efficacy of the selective-serotonin reuptake inhibitor fluoxetine (FLX)
83 threo-dihydroxyphenylserine at 5 mg/kg) or a selective serotonin reuptake inhibitor (fluoxetine at 20
84 e individually exposed to acute doses of the selective serotonin reuptake inhibitor, fluoxetine (5 or
86 l or progesterone blocked the ability of the selective serotonin reuptake inhibitor, fluvoxamine, to
87 d trials began demonstrating the efficacy of selective serotonin reuptake inhibitors for these condit
88 ial direct-current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment
89 matized IF-CCKR-2 tg mice with fluoxetine, a selective serotonin reuptake inhibitor, for a period of
93 Although cognitive behavioral therapy and selective serotonin-reuptake inhibitors have shown effic
94 cerebral cortex are powerfully modulated by selective serotonin reuptake inhibitors, however, direct
95 SADHART) tested the safety and efficacy of a selective serotonin reuptake inhibitor in this populatio
96 ajor randomized placebo-controlled trials of selective serotonin reuptake inhibitors in adolescents h
98 sk estimates for each drug individually, for selective serotonin reuptake inhibitors in depression tr
102 ctively over a 12-week treatment course with selective serotonin reuptake inhibitors in late-life dep
103 the use of cognitive behavioral therapy and selective serotonin reuptake inhibitors in the treatment
106 the number of children exposed prenatally to selective serotonin reuptake inhibitors in this populati
108 take and biological effects of fluoxetine, a selective serotonin reuptake inhibitor, in filter and de
109 profile of using antidepressants, especially selective serotonin reuptake inhibitors, in depressed ch
110 outcomes, but antidepressant treatment with selective serotonin reuptake inhibitors is generally saf
114 d MDDs (untreated, n = 12), MDD treated with selective serotonin reuptake inhibitors (MDD*SSRI, n = 6
115 trials of second-generation antidepressants (selective serotonin reuptake inhibitors, nefazodone, ven
116 Use of selective serotonin reuptake inhibitors, nonbenzodiazepi
117 with depression classified as responsive to selective serotonin reuptake inhibitors (odds ratio=1.55
118 estigations into the effects of OLZ, but not selective serotonin reuptake inhibitors, on core feature
119 o ongoing antidepressant medication therapy (selective serotonin reuptake inhibitor or serotonin and
120 health and physical health, treatment with a selective serotonin reuptake inhibitor or serotonin-nore
121 nd were randomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, w
122 wed by a 10-week open-label treatment with a selective serotonin reuptake inhibitor or, in some cases
123 xib, ondansetron) either in combination with selective serotonin reuptake inhibitors or as monotherap
124 rol in the treatment of depression by use of selective serotonin reuptake inhibitors or psychological
125 macologically untreated maternal depression, selective serotonin reuptake inhibitors or serotonin and
126 ctively downregulated by the acute action of selective serotonin reuptake inhibitors or serotonin at
127 dence interval [CI] = 1.10-15.14) and use of selective serotonin reuptake inhibitors (OR = 2.66; 95%
128 er, this includes tricyclic antidepressants, selective serotonin reuptake inhibitors, or psychosocial
131 cognitive behavioral therapy with or without selective serotonin reuptake inhibitors remains a prefer
133 ticularly in women with MDD or anxiety, with selective serotonin reuptake inhibitors reported as the
134 effects of classic antidepressants, such as selective serotonin reuptake inhibitors, require a month
135 tion, acute itch triggered by serotonin or a selective serotonin reuptake inhibitor required both HTR
136 r adolescent exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, results in chang
137 Only one case report suggested benefit from selective serotonin reuptake inhibitor/serotonin-norepin
138 re may be excess morbidity in critically ill selective serotonin reuptake inhibitor/serotonin-norepin
140 ed for studies of ICU patients with recorded selective serotonin reuptake inhibitor/serotonin-norepin
141 ting, it was generally unclear if outpatient selective serotonin reuptake inhibitor/serotonin-norepin
142 istics in exposed and control groups; use of selective serotonin reuptake inhibitor/serotonin-norepin
143 needed to help clinicians decide when to use selective serotonin reuptake inhibitor/serotonin-norepin
144 8 weeks of antidepressant treatment with the selective serotonin reuptake inhibitor sertraline hydroc
146 als have indicated that the combination of a selective serotonin reuptake inhibitor (SSRI) and a stat
147 e disorder, either untreated or treated with selective serotonin reuptake inhibitor (SSRI) antidepres
148 antidepressant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepres
149 DA, and displays distinct sensitivity to the selective serotonin reuptake inhibitor (SSRI) antidepres
150 d by 25% following administration of several selective serotonin reuptake inhibitor (SSRI) antidepres
151 cal antipsychotic medications; fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepres
156 ing Caucasian subjects were administered the selective serotonin reuptake inhibitor (SSRI) citalopram
157 lacked the early anxiogenic response to the selective serotonin reuptake inhibitor (SSRI) fluoxetine
158 acy in rats and advantages compared with the selective serotonin reuptake inhibitor (SSRI) fluoxetine
159 depressant (TCA) desipramine (10 mg/kg), the selective serotonin reuptake inhibitor (SSRI) fluoxetine
160 pothesis that 6 weeks' administration of the selective serotonin reuptake inhibitor (SSRI) fluoxetine
162 study revealed that chronic treatment with a selective serotonin reuptake inhibitor (SSRI) impairs th
164 an empirically supported psychotherapy with selective serotonin reuptake inhibitor (SSRI) pharmacoth
165 le-blind, randomized controlled trial of the selective serotonin reuptake inhibitor (SSRI) sertraline
167 e disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy.
168 compounds was synthesized by linking a novel selective serotonin reuptake inhibitor (SSRI) to a PDE4
170 s examined the relationship between prenatal selective serotonin reuptake inhibitor (SSRI) treatment
172 porter (hSERT) were synthesized based on the selective serotonin reuptake inhibitor (SSRI), (S)-cital
175 postnatal days 8-21) exposure of rats to the selective serotonin reuptake inhibitor (SSRI), citalopra
177 ors that are not rescued with the prototypic selective serotonin reuptake inhibitor (SSRI), fluoxetin
178 investigated the effects of escitalopram, a selective serotonin reuptake inhibitor (SSRI), on brain
179 -up analyses demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), provided
185 Here, we show that when the effects of a selective serotonin reuptake inhibitor (SSRI, citalopram
189 ve demonstrated that acute administration of selective serotonin reuptake inhibitors (SSRI) can affec
190 ible association between maternal use of the selective serotonin-reuptake inhibitor (SSRI) fluoxetine
191 unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not
192 ar mechanisms explaining hormetic effects of selective serotonin reuptake inhibitors (SSRIs) and 4-no
193 seems to be a correlation between the use of selective serotonin reuptake inhibitors (SSRIs) and a de
195 olescents in randomized controlled trials to selective serotonin reuptake inhibitors (SSRIs) and cons
196 lasses of antidepressants, prescriptions for selective serotonin reuptake inhibitors (SSRIs) and othe
197 ike behaviors, both of which are reversed by selective serotonin reuptake inhibitors (SSRIs) and the
218 cern about an association between the use of selective serotonin reuptake inhibitors (SSRIs) during p
220 e has been ongoing controversy as to whether selective serotonin reuptake inhibitors (SSRIs) exhibit
221 of suicidality in pediatric patients taking selective serotonin reuptake inhibitors (SSRIs) for depr
222 of suicidality in pediatric patients taking selective serotonin reuptake inhibitors (SSRIs) for depr
223 .S. and Dutch data on prescription rates for selective serotonin reuptake inhibitors (SSRIs) from 200
228 xamined modulation of synaptic plasticity by selective serotonin reuptake inhibitors (SSRIs) in hippo
229 ies suggested that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major
230 r (nAChR) blockers potentiate the effects of selective serotonin reuptake inhibitors (SSRIs) in some
231 sion and attention, and the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in treat
232 rs investigated whether in utero exposure to selective serotonin reuptake inhibitors (SSRIs) increase
235 d, treating animals with MAO-A inhibitors or selective serotonin reuptake inhibitors (SSRIs) normaliz
236 was to assess the effects of treatment with selective serotonin reuptake inhibitors (SSRIs) on the r
237 placebo in meta-analyses of 7 comparisons of selective serotonin reuptake inhibitors (SSRIs) or serot
238 dicines (CSM) advised against treatment with selective serotonin reuptake inhibitors (SSRIs) other th
241 ted with PD, and clinical data indicate that selective serotonin reuptake inhibitors (SSRIs) such as
242 and its eutomer, escitalopram (S-(+)-1) are selective serotonin reuptake inhibitors (SSRIs) that are
243 s risk from concomitant use of nsNSAIDs with selective serotonin reuptake inhibitors (SSRIs) was 1.6,
245 recent studies linking in utero exposure to selective serotonin reuptake inhibitors (SSRIs) with per
246 erotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and mat
247 n between use of antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), and sui
248 ion do not respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), and thi
249 ear how perinatal exposure to drugs, such as selective serotonin reuptake inhibitors (SSRIs), impacts
251 rapy were compared for patients who received selective serotonin reuptake inhibitors (SSRIs), new-gen
252 broad range of therapeutic agents including selective serotonin reuptake inhibitors (SSRIs), seroton
253 t of several antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), seroton
254 examine the relative efficacy and safety of selective serotonin reuptake inhibitors (SSRIs), seroton
256 lizers, which dampen limbic irritability, or selective serotonin reuptake inhibitors (SSRIs), which m
257 nteraction of fluoxetine and paroxetine, two selective serotonin reuptake inhibitors (SSRIs), with th
270 the population and is commonly treated with selective serotonin reuptake inhibitors (SSRIs; e.g., Pr
272 HMG-CoA) reductase inhibitors (statins), and selective serotonin-reuptake inhibitors (SSRIs) and sero
274 of birth defects after antenatal exposure to selective serotonin-reuptake inhibitors (SSRIs) remains
275 (DR) attenuates the therapeutic activity of selective serotonin-reuptake inhibitors (SSRIs), whereas
277 ed duloxetine to comparators (venlafaxine or selective serotonin reuptake inhibitors [SSRIs], and ind
278 s, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors, statins, and th
279 unintended declines in case finding and non-selective serotonin reuptake inhibitor substitute treatm
281 urtailed with subchronic administration of a selective serotonin reuptake inhibitor, suggesting the p
283 participants who required the addition of a selective serotonin reuptake inhibitor to achieve remiss
285 Behavioral changes were rescued by acute selective serotonin reuptake inhibitor treatment, suppor
290 nonbenzodiazepine hypnotics, beta-blockers, selective serotonin reuptake inhibitors, tricyclic antid
291 according to whether patients were receiving selective serotonin reuptake inhibitors, tricyclic antid
292 ed to compute odds ratios for differences in selective serotonin reuptake inhibitor use between cases
298 ry cohort of 6024 residents, 1024 (17%) were selective serotonin reuptake inhibitor users compared to
300 articipants who were partial responders to a selective serotonin reuptake inhibitor were randomized t
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。